Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of an intranasally administered live attenuated PRRSV-2 vaccine against challenge with a highly virulent PRRSV-1 strain

22 Aug 2025

Abstract excerpt

Introduction The emergence of highly virulent strains of the porcine reproductive and respiratory syndrome virus has driven the need for new vaccines. This study evaluates the efficacy of an intranasal (IN) vaccine composed of a naturally attenuated PRRSV-2 isolate, compared to a commercially available intramuscularly administered (IM) PRRSV-1 vaccine, against a heterologous challenge with a highly virulent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Virus Infections Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to Virology and Viral Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40919027
DOI: 10.3389/fvets.2025.1619052

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of an intranasally administered live attenuated PRRSV-2 vaccine against challenge with a highly virulent PRRSV-1 strainPMID 40919027Read ↗

Comparison of Host Immune Responses to Homologous and Heterologous Type II Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) Challenge in Vaccinated and Unvaccinated PigsSemantic proximity Read ↗

Protective Efficacy of an mRNA Vaccine Against HP-PRRSV Challenge in PigletsSemantic proximity Read ↗

Commercial PRRS Modified-Live Virus VaccinesSemantic proximity Read ↗

Intradermal and intramuscular vaccination with a modified live vaccine against porcine reproductive and respiratory syndrome 1 (PRRS1) induce similar levels of neutralising antibodies or interferon-gamma secreting cells in the presence of maternally derived antibodiesSemantic proximity Read ↗

Simultaneous infection with porcine reproductive and respiratory syndrome and influenza viruses abrogates clinical protection induced by live attenuated porcine reproductive and respiratory syndrome vaccinationSemantic proximity Read ↗

Porcine Reproductive and Respiratory Syndrome Modified Live Virus Vaccine: A “Leaky” Vaccine with Debatable Efficacy and SafetySemantic proximity Read ↗

Immunological solutions for treatment and prevention of porcine reproductive and respiratory syndrome (PRRS).Semantic proximity Read ↗

Vaccine Efficacy of a Replication-Competent Interferon-Expressing Porcine Reproductive and Respiratory Syndrome (PRRS) Virus against NADC-34 ChallengeSemantic proximity Read ↗

Current Status of Porcine Reproductive and Respiratory Syndrome VaccinesSemantic proximity Read ↗

Comparison of Two Commercial Type 1 Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) Modified Live Vaccines against Heterologous Type 1 and Type 2 PRRSV Challenge in Growing PigsSemantic proximity Read ↗

Comparison of commercial type 1 and type 2 PRRSV vaccines against heterologous dual challenge.Semantic proximity Read ↗

An attenuated live vaccine based on highly pathogenic porcine reproductive and respiratory syndrome virus (HP-PRRSV) protects piglets against HP-PRRSSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.